Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2011

View Archived Issues

Astellas Pharma reviews progress of second quarter fiscal year 2011

First-in-human data released on candidate hepatitis C therapy

AstraZeneca reviews progress of third quarter 2011

Hepatitis C virus resistance characterized in multiple-dose trial of GS-5885

LB-80380 compared to entecavir in phase IIb trial

Tocilizumab assessed in large vessel vasculitis

Ampio Pharmaceuticals reports on Ampion for nasal inflammation

Scancell to receive second tranche payment for antibody portfolio

Novel clinical data and analyses presented on Regeneron's rilonacept

PRT-201 shows promise in patients with kidney disease on hemodialysis

New PHD2 inhibitors for anemia patented

Merck & Co. prepares novel fatty-acid amide hydrolase 1 inhibitors

Novel lysophospholipid S1P1 receptor agonists disclosed by Bristol-Myers Squibb

Glenmark Pharmaceuticals claims novel phosphodiesterase 10A inhibitors

Scientists at Janssen synthesize new ketohexokinase inhibitors

Pharmacokinetics and safety of E-7050 assessed in humans

High-strength antidepressant gains FDA approval

FDA removes clinical hold on Helix BioPharma IND application

Analgesia seen with NP-2 in phase I study

Ablynx announces proof-of-concept phase II data on ALX-0081

FDA schedules review of NDA for progesterone vaginal gel

Alimera receives complete response letter for Iluvien NDA

EC withdraws marketing authorization for Ablavar

Phase III study in MS meets primary endpoints

Kyowa Hakko Kirin and Cephalon begin clinical testing of CEP-37250

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...